肾移植受者、血液透析患者、血液恶性肿瘤患者及健康对照者的疲劳、焦虑、抑郁与生活质量比较
该横断面队列研究纳入168例受试者,包括血液透析患者、肾移植受者、接受化疗或处于缓解期的血液恶性肿瘤患者及健康对照,使用SF-36、CIS和HADS问卷评估疲劳、焦虑、抑郁与生活质量。结果显示血液透析和化疗患者严重疲劳及抑郁比例最高、生活质量最低,肾移植受者优于透析患者但总体生活质量仍低于健康对照。
要点
- 血液透析患者严重疲劳比例53.3%,高于肾移植受者的33.3%和健康对照的12.1%。
- 血液透析患者抑郁比例33.3%,肾移植受者16.7%,健康对照8.6%,组间差异P=0.066。
- 肾移植受者报告最大的正向健康变化(+27%,P<0.001),但总体生活质量仍低于健康对照。
核心结论
- 疲劳和抑郁在血液透析患者中常见,导致其生活质量低,与接受化疗的血液恶性肿瘤患者相当。
- 肾移植受者情况较好,评分与缓解期血液恶性肿瘤患者相似,但生活质量仍低于健康对照。
研究设计与样本
- 横断面队列研究,共纳入168例患者,包括血液透析患者、肾移植受者、接受化疗或处于缓解期的血液恶性肿瘤患者及健康对照。
- 所有参与者完成36项健康相关生活质量简表(SF-36)、个体强度检查表(CIS)和医院焦虑抑郁量表(HADS)问卷。
主要发现
- 血液透析患者和接受化疗的血液恶性肿瘤患者严重疲劳比例分别为53.3%和50%,高于肾移植受者的33.3%、缓解期血液恶性肿瘤患者的23.3%和健康对照的12.1%(P<0.001)。
- 焦虑率组间无显著差异。
- 血液透析患者和接受化疗的血液恶性肿瘤患者最可能抑郁(33.3%和25%),肾移植受者为16.7%,缓解期血液恶性肿瘤患者为20%,健康对照为8.6%(P=0.066)。
- 肾移植受者报告最大的正向健康变化(+27%,P<0.001),但总体生活质量仍低于健康对照,与缓解期血液恶性肿瘤患者相当。
- 血液透析和化疗患者报告最低的生活质量评分。
临床怎么用
- 应关注血液透析患者的疲劳和抑郁,其生活质量与接受化疗的血液恶性肿瘤患者相当。
- 肾移植受者生活质量优于透析患者但仍低于健康对照,需持续评估和管理。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The impact of haemodialysis (HD) and kidney transplantation on quality of life (QoL) is often underestimated due to a lack of comparative studies with other patient groups. METHODS: We conducted a cross-sectional cohort study in 168 patients including HD patients, kidney transplant recipients (KTR), patients with a haematological malignancy either receiving chemotherapy or in remission and healthy controls. All participants completed the 36-item short form survey of health-related quality of life, the Checklist Individual Strength and the Hospital Anxiety and Depression Scale questionnaire. RESULTS: HD patients and haematological patients undergoing chemotherapy were more frequently severely fatigued (53.3% and 50% of cases) compared with KTR (33.3%), haematological patients in remission (23.3%) and healthy controls (12.1%, P < 0.001). There were no significant differences in anxiety rates. HD patients and haematological patients undergoing chemotherapy were most likely to be depressed (33.3% and 25%), compared with 16.7% of KTR, 20% of haematological patients in remission and 8.6% of healthy controls (P = 0.066). KTR reported the largest positive health change (+27%, P < 0.001), but still had a lower overall QoL than healthy controls, comparable to haematological patients in remission. HD and chemotherapy patients reported the lowest QoL scores. CONCLUSIONS: Fatigue and depression are common in HD patients, resulting in a low QoL, comparable to haematological patients receiving chemotherapy. KTR do better, with scores similar to patients with a haematological malignancy in remission, but still have a lower QoL than healthy controls.
引用
- van Sandwijk MS, Al Arashi D, van de Hare FM, et al. Fatigue, anxiety, depression and quality of life in kidney transplant recipients, haemodialysis patients, patients with a haematological malignancy and healthy controls. Nephrol Dial Transplant. 2019. PMID: 29726909. doi:10.1093/ndt/gfy103
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。